Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOX | P28300 | 14/20 | 1.00 |
| ▸ | LOXL2 | Q9Y4K0 | 9/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | AOC3 | Q16853 | 2/20 | 1.00 |
| ▸ | LOXL3 | P58215 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30846484 | 0.99 | LOX (0.97) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19259977 | 0.89 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19274591 | 0.88 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19259962 | 0.88 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL20983542 | 0.87 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| Hydrochloric Acid SCHEMBL19259609 | 0.86 | LOX (0.98) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19274554 | 0.86 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19274713 | 0.85 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL29970885 | 0.85 | LOX (1.00) | LOXLOXL2KCNH2AOC3LOXL3 | |
| SCHEMBL19274855 | 0.85 | LOXL2 (1.00) | LOXLOXL2KCNH2AOC3LOXL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116531367-B | Application of CCT365623 in preparation of medicine for treating parkinsonism | 中南大学湘雅医院 | 2024-04-19 | — | — | CN | claimed |
| EP-4314018-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | Baylor College of Medicine (US) | 2024-02-07 | — | — | EP | claimed |
| US-20230355711-A1 | VIMENTIN AND FRAGMENTS OR DERIVATIVES THEREOF FOR CORONAVIRUS TREATMENT AND PREVENTION | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2023-11-09 | — | — | US | claimed |
| CN-116531367-A | Application of CCT365623 in preparation of medicines for treating parkinsonism | 中南大学湘雅医院 | 2023-08-04 | — | — | CN | claimed |
| US-20230210902-A1 | SARS-COV-2-SPECIFIC T CELLS | NATIONAL INSTITUTES OF HEALTH | 2023-07-06 | — | — | US | claimed |
| EP-4149496-A1 | SARS-COV-2-SPECIFIC T CELLS | Board of Regents, The University of Texas System (US) | 2023-03-22 | — | — | EP | claimed |
| US-20220401553-A1 | PARAPOXVIRUS FOR CONDITIONING FOR AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO. KG (DE) | 2022-12-22 | — | — | US | claimed |
| WO-2022213076-A1 | METHODS AND COMPOSITIONS FOR HIGH-POTENCY POLYPEPTIDE-BASED PROTEIN INHIBITION | BAYLOR COLLEGE OF MEDICINE (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3906970-B1 | PARAPOXVIRUS FOR CONDITIONING AND TREATMENT OF CORONAVIRUS INFECTIONS | AICURIS GMBH & CO KG (DE) | 2022-07-06 | — | — | EP | claimed |
| US-20220193204-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | BAYLOR COLLEGE OF MEDICINE (US) | 2022-06-23 | — | — | US | claimed |
| EP-3969036-A1 | USES OF A2 DOMAIN OF VON WILLEBRAND FACTOR | Baylor College of Medicine (US) | 2022-03-23 | — | — | EP | claimed |
| EP-4714452-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | Gilead Sciences, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4642465-A1 | A CANCER ASSOCIATED FIBROBLAST (CAF) INHIBITOR FOR USE WITH AN ALTERNATING ELECTRIC FIELD IN A METHOD OF TREATING DISEASES SUCH AS CANCER | Novocure GmbH (CH) | 2025-11-05 | — | — | EP | disclosed |
| EP-4581011-A1 | NOVEL SELECTIVE INHIBITORS OF LYSYL OXIDASES | Syntara Limited (AU) | 2025-07-09 | — | — | EP | disclosed |
| CN-119968356-A | Novel lysyl oxidase selective inhibitors | 辛塔拉有限公司 | 2025-05-09 | — | — | CN | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | LOX 4/4885LOXL2 3/4885KCNH2 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.